YL-201
- Generic Name
- YL-201
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06898957
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06629597
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT06612151
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT06394414
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, beijinig, China
A Study of YL201 in Patients with Advanced Solid Tumors
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT05434234
- Locations
- 🇺🇸
University California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.